CureVac study shows COVID jab only 47% efficient

Mittwoch, 16. Juni 2021 23:01

CureVac N.V. unveiled on Wednesday the intermediary results from their latest phase of the coronavirus vaccine trials that showed that their vaccine was only 47% efficient against the global virus.

According to the company's press release, the result "did not meet prespecified statistical success criteria," adding that the efficacy was also dependent on age and the virus variant. Moreover, while younger participants were more receptive to the vaccine, the pharmaceutical firm couldn't conclude that the vaccine was effective in those over 60 from the provided data.

Dr. Franz-Werner Haas, Chief Executive Officer of CureVac, commented on the results: "While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging."

Shares of CureVac plummetted 52.53% in the after-hours trade following the news.

Kapcsolódó linkek: Curevac N.V.
Breaking the News / OL